Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Verywell Health on MSN
What you need to know about COVID arm rash
Medically reviewed by Renee Nilan, MD Key Takeaways COVID arm rash is a mild reaction that usually appears a week after the ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites ...
FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results